8-K: Aimei Health and United Hydrogen Extend Merger Deadline to September 2025

Aimei Health Technology Co., Ltd. and United Hydrogen Group Inc. have amended their Business Combination Agreement, extending the deadline for completing their merger to September 30, 2025.

Summary

• Aimei Health Technology Co., Ltd. (Aimei Health) and United Hydrogen Group Inc. (United Hydrogen) entered into an amendment to their Business Combination Agreement on June 6, 2025.
• The amendment specifically extends the 'Outside Date' for the completion of the business combination from March 31, 2025, to September 30, 2025.
• This 'Outside Date' is the deadline by which conditions to the closing of the merger must be satisfied or waived.
• The original Business Combination Agreement was dated June 19, 2024, involving Aimei Health, United Hydrogen, and several Acquisition Entities (Pubco, First Merger Sub, Second Merger Sub), and Aimei Investment Ltd. as Purchaser Representative.
• The filing emphasizes that the description of the amendment is not complete and is qualified by the full terms and conditions of the Amendment, attached as Exhibit 2.1.

Sentiment

Score: 4

Explanation: The sentiment is slightly negative due to the delay in the business combination, which introduces uncertainty and suggests challenges in meeting the original timeline. While the extension keeps the deal alive, it signals a slower-than-expected progression.

Positives

• The extension of the 'Outside Date' indicates that both parties remain committed to completing the business combination, providing additional time to satisfy closing conditions.

Negatives

• The necessity of extending the merger deadline suggests that the parties were unable to meet the original March 31, 2025, target, indicating potential delays or complexities in satisfying closing conditions.
• Delays in business combinations can introduce uncertainty and potentially erode investor confidence.

Risks

• The occurrence of any event, change, or other circumstances that could give rise to the termination of negotiations and any subsequent definitive agreements with respect to the Business Combination.
• The outcome of any legal proceedings that may be instituted against Aimei Health, United Hydrogen, or others following the announcement of the Business Combination.
• The inability to complete the Business Combination due to the failure to obtain shareholder approval or to satisfy other conditions to closing, including governmental and regulatory approvals.
• Changes to the proposed structure of the Business Combination that may be required or appropriate as a result of applicable laws or regulations or as a condition to obtaining regulatory approval.
• The inability to meet applicable stock exchange listing standards following the consummation of the Business Combination.
• The risk that the Business Combination disrupts current plans and operations of United Hydrogen or its subsidiaries.
• The effect of the announcement or pendency of the transaction on United Hydrogen's business relationships, operating results, and business generally.
• The inability to recognize the anticipated benefits of the Business Combination, which may be affected by competition, United Hydrogen's ability to grow and manage growth profitably, maintain relationships with customers and suppliers, and retain its management and key employees.
• Costs related to the Business Combination.
• Volatility of Aimei Health's securities price due to factors such as changes in competitive and regulated industries, variations in operating performance, changes in laws and regulations, inability to implement business plans or meet financial projections, and changes in the combined capital structure.
• Changes in applicable laws or regulations, including legal or regulatory developments (e.g., accounting considerations) which could result in unforeseen delays and negatively impact the trading price of Aimei Health's securities and the attractiveness of the Business Combination.
• The possibility that Aimei Health and United Hydrogen may be adversely affected by other economic, business, and/or competitive factors.
• United Hydrogen's ability to execute its business plans and strategies.
• United Hydrogen's estimates of expenses and profitability.
• The amount of redemption requests made by Aimei Health's public shareholders.
• The risk that the transaction may not be completed by Aimei Health's business combination deadline and the potential failure to obtain extensions of the business deadline if sought.
• The effects of natural disasters, terrorist attacks, and the spread and/or abatement of infectious diseases, such as COVID-19, on the proposed transactions or on the ability to implement business plans and forecasts.

Future Outlook

The extension of the 'Outside Date' to September 30, 2025, indicates the parties' continued intent to complete the business combination. However, the document highlights numerous forward-looking risks that could prevent the successful completion of the merger, including regulatory approvals, shareholder consent, and the ability to realize anticipated benefits.

Management Comments

• Junheng Xie, Chief Executive Officer and Director of Aimei Health Technology Co., Ltd., signed the 8-K filing.
• Xia Ma, Director of United Hydrogen Global Inc., United Hydrogen Victor Limited, United Hydrogen Worldwide Limited, and United Hydrogen Group Inc., signed the First Amendment to Business Combination Agreement.

Industry Context

This amendment reflects the ongoing complexities and potential delays often encountered in significant business combinations, particularly those involving cross-border entities or emerging growth companies. Such extensions are not uncommon when regulatory approvals, due diligence, or other closing conditions require more time than initially anticipated.

Stakeholder Impact

• Shareholders of Aimei Health will need to vote on the proposed business combination, and the delay may affect their investment timeline and perception of the deal's certainty.
• Employees of both Aimei Health and United Hydrogen may experience continued uncertainty regarding the future structure and operations of the combined entity.
• The delay could impact business relationships for United Hydrogen with customers and suppliers, as well as its operating results, as mentioned in the forward-looking statements.

Next Steps

• Pubco is expected to file a registration statement on Form F-4, including a preliminary proxy statement of Aimei Health and a registration statement/preliminary prospectus of Pubco.
• After the Registration Statement is declared effective, Aimei Health will mail a definitive proxy statement/prospectus and other relevant documents to its shareholders for voting on the proposed transactions.
• Aimei Health and Pubco will also file other documents regarding the proposed transactions with the SEC.
• Investors and security holders are urged to read the registration statement, proxy statement/prospectus, and all other relevant documents when they become available before making any voting or investment decisions.

Key Dates

Keywords

Business Combination Agreement, Merger, SEC Filing, 8-K, Aimei Health Technology, United Hydrogen Group, Merger Deadline Extension, Corporate Governance, Acquisition, Nasdaq